Abbott Files Simcor With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Combination of niacin and simvastatin will address LDL, HDL and triglycerides in a single pill.
You may also be interested in...
Abbott’s Simcor Significantly Lowers Non-HDL Cholesterol In SEACOAST Phase III Study
Simcor, with a Feb. 20 user fee date, could face competition from two Merck investigational extended-release niacin combinations, including Cordaptive (laropiprant), with an anticipated FDA action date in Q2 2008.
Abbott’s Simcor Significantly Lowers Non-HDL Cholesterol In SEACOAST Phase III Study
Simcor, with a Feb. 20 user fee date, could face competition from two Merck investigational extended-release niacin combinations, including Cordaptive (laropiprant), with an anticipated FDA action date in Q2 2008.
Abbott Partners With Solvay On Simcor Ahead Of Planned 2008 Launch
Solvay will provide sales support in the U.S. in addition to funding development and promotions for the Niaspan/simvastatin combination.